

Surgical treatment of Epstein-Barr virus-associated lymphoepithelioma-like carcinoma occurring in both the posterior mediastinum and liver

Case report

Xiao-Hui Qian, MD^{a,b,c,d,e}, Dong-Kai Zhou, MD^{a,b,c,d,e}, Wei-Lin Wang, MD, PhD^{a,b,c,d,e,*}

Abstract

Rationale: Lymphoepithelioma-like carcinoma (LELC) is a rare malignant tumor that can occur in many areas of the body. The pathogenesis of LELC remains unknown, but Epstein-Barr virus (EBV) has been shown to be strongly correlated with LELC at several anatomic sites, including the lungs and thymus. To the best of our knowledge, EBV-associated LELC has never been reported in both the posterior mediastinum and liver. Herein, we report the case of a 41-year-old female diagnosed with LELC in both the posterior mediastinum and liver and discuss whether it is beneficial to perform surgery on advanced LELC when resectable metastases are found.

Patient concerns: The patient was a 41-year-old woman who had been suffering from intermittent pain in the upper right quadrant for 3 months without obvious cause and was admitted to our hospital with occasional nausea without vomiting.

Diagnosis: Her cancer antigen 125 and cytokeratin 19 fragment levels were elevated, whereas alpha-fetoprotein and alanine aminotransferase were normal. Computed tomography (CT) and magnetic resonance imaging revealed a mass in the S6 segment of the liver. Whole-body positron emission tomography/computed tomography (PET/CT) revealed a 3.2-cm mass in the posterior mediastinum and a 6.7-cm mass on the right side of the liver. We made a diagnosis of LELC based on the histological and immunohistochemical findings of specimens obtained by operation. However, it was difficult to determine the primary origin of the tumor.

Interventions: The patient underwent mediastinal tumor resection, hepatectomy, and diaphragmatic repair. Thereafter, she was administered paclitaxel and cisplatin as adjuvant chemotherapy.

Outcomes: The postoperative course was uneventful, and the patient was discharged 10 days later. Although she was administered paclitaxel and cisplatin as adjuvant chemotherapy, we noted recurrence during the 4-month follow-up examination. Then, the patient passed away 5 months after surgery.

Lessons: We present the first case of LELC found in both the posterior mediastinum and liver and describe the functionality of PET/ CT for finding occult carcinomas and identifying their primary tumor origin. Additional studies are urgently needed to discover whether it is beneficial to perform surgery on advanced LELC when resectable metastases are revealed by PET/CT.

This work was supported by the National Natural Science Foundation of China (No. 81572307 and 81773096) and the Major Project of Medical and Health Technology Development Program in Zhejiang Province (No. 7211902).

The authors have no funding and conflicts of interest to disclose.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

^a Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, ^b Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Turnor of Zhejiang Province, ^c Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, ^d Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, ^e Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, China.

* Correspondence: Wei-Lin Wang, Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang 310009, China (e-mail: wam@zju.edu.cn).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

Received: 21 December 2019 / Received in final form: 15 July 2020 / Accepted: 10 November 2020

http://dx.doi.org/10.1097/MD.000000000023610

Editor: Maya Saranathan.

Ethical statement: Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images. Ethical approval was obtained from the Ethics Committee of the Second Affiliated Hospital, School of Medicine, Zhejiang University, China, in accordance with the ethical guidelines of the 1975 Declaration of Helsinki.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Qian XH, Zhou DK, Wang WL. Surgical treatment of Epstein-Barr virus-associated lymphoepithelioma-like carcinoma occurring in both the posterior mediastinum and liver: Case report. Medicine 2020;99:52(e23610).

Abbreviations: AFP = alpha-fetoprotein, CA 125 = cancer antigen 125, CT = computed tomography, CYFRA 21-1 = cytokeratin 19 fragments, EBER = EBV-encoded RNA, EBV = Epstein-Barr virus, HCC = hepatocellular carcinoma, ISH = in situ hybridization, LELC = lymphoepithelioma-like carcinoma, MRI = magnetic resonance imaging, PET/CT = positron emission tomography/ computed tomography, PLELC = pulmonary lymphoepithelioma-like carcinoma.

Keywords: case report, lymphoepithelioma-like carcinoma, positron emission tomography/computed tomography, posterior mediastinum, surgery

1. Introduction

Lymphoepithelioma-like carcinoma (LELC), which is a form of undifferentiated carcinoma characterized by abundant lymphoid components, was originally described in the nasopharynx.^[1] More recently, these tumors have been reported to occur in several organs, including the salivary glands,^[2] lungs,^[3] stomach,^[4] and liver.^[5] The thymus and lungs are the most common locations for primary mediastinal LELCs.^[6] However, an LELC originating from the posterior mediastinum has not been previously reported. Primary LELCs of the liver, which have only recently been recognized by the World Health Organization as a variant of hepatocellular carcinoma (HCC) (LEL-HCC), are also rare.^[7] The pathogenesis of LELC remains unknown, but Epstein-Barr virus (EBV) has been shown to be strongly correlated with LELC at several anatomic sites, including the lungs and thymus.^[8] Regardless of origin, the morphological features and prognosis of LELC appear to be the same based on the limited information that has been reported. To the best of our knowledge, LELC has never been reported in both the posterior mediastinum and liver. Herein, we report the case of a 41-yearold woman diagnosed with LELC in both the posterior mediastinum and liver, and we review the literature on treatments for LELC.

2. Case report

The patient was a 41-year-old woman who had been suffering from abdominal pain and nausea for 3 months before evaluation. She had experienced intermittent pain in the upper right quadrant for 3 months without obvious cause and occasional nausea with no vomiting but did not exhibit fever, diarrhea, or abdominal distension. She underwent ovarian cystectomy 10 years prior and had no history of infection with hepatitis B or C. Her other medical and family histories were unremarkable. She did not smoke and seldom drank. Abdominal palpation revealed mild pain lacking rebound tenderness in the upper right quadrant. The level of cancer antigen 125 (CA 125) was 65.2 U/mL (normal range 0.0-35.0U/mL), and the level of cytokeratin 19 fragments (CYFRA 21-1) was 60.7 ng/mL (normal range 0.0-60.7 U/mL). Alpha-fetoprotein (AFP), total bilirubin, and alanine aminotransferase were within normal ranges. Enhanced abdominal computed tomography (CT) revealed a 6.7-cm hypodense lesion in the S6 segment of the liver. A 6.7×5.4 -cm hepatic mass was found on magnetic resonance imaging (MRI). The T1 image showed a low signal, whereas T2 and diffusion-weighted imaging showed a high signal. The contrast-enhanced images showed a mixed signal (Fig. 1). A biopsy sample from the hepatic lesion indicated LELC with probable metastasis. She was referred for whole-body positron emission tomography/computed tomography (PET/CT), which revealed a 3.2-cm mass in the posterior mediastinum and a 6.7-cm mass on the right lobe of the liver, as well as lymphadenopathy in the hepatic portal region and

posterior peritoneum (Fig. 2). The lungs and stomach, which are common sites for LELC, showed no signs of abnormality. After consulting with colleagues and taking all diagnostic findings into account, we decided that resection surgery of the LELC was the best course of action. We began resection surgery in cooperation with the doctors from the thoracic surgery department after obtaining informed consent from the patient and her relatives. We first found the hepatic tumor, which was dark red and measured approximately 8×6 cm, located in the S6 segment with clear boundaries. We separated the ligaments around the liver, dissected the first, second, and third hepatic hila, and began to completely remove the liver tumors along the 2 cm of the tumor boundary. After hemostasis was completed, the diaphragm was opened with an electric knife along the inferior vena cava, as planned. The mediastinal tumor $(3 \times 2 \text{ cm})$ lay behind the postcava with lymphadenopathy $(1.5 \times 1 \text{ cm})$. We found no other metastases, and there was no obvious adhesion between the tumor and the surrounding area. Thus, we finally performed mediastinal tumor resection, hepatectomy, and diaphragmatic repair. Microscopically, the neoplasms were full of poorly differentiated epithelial cells with eosinophilic nucleoli. The epithelial cells were surrounded by dense lymphoid stroma extending inside the tumor. The immunohistochemical analysis was CD3+, CD5+, CD20+, CD5/6+, P63+, CK-pan+, EBVencoded RNA+ (EBER+), hepatocyte-, and AFP- (Fig. 3). Ki-67 was present in 40% of malignant cells. A diagnosis of LELC was made based on the histological and immunohistochemical findings, and the posterior mediastinum was determined to be the likely primary region of origin. The postoperative course was uneventful, and the patient was discharged 10 days later. Thereafter, she was administered paclitaxel and cisplatin as adjuvant chemotherapy, and we noted recurrence during the 4month follow-up examination. The patient passed away 1 month later.

3. Discussion

LELC was initially discovered in the 1920s in the nasopharynx of patients infected with EBV.^[1] Since then, more cases originating from a variety of organs have been described, including the salivary glands and stomach. These tumors are characterized by undifferentiated carcinoma cells with abundant infiltrating lymphocytes.^[7] Although the pathogenesis of LELC remains unknown, it has been correlated with various viral infections, such as EBV in the lungs,^[9] HBV in the liver,^[10] and HPV in the genitals.^[11] An in situ hybridization (ISH) test for EBER is generally used to distinguish LELC from other lung cancers.^[9] A favorable prognosis has been proposed in EBV-associated LELC arising in the stomach, lungs, and uterine cervix.^[12–14] In our present patient, the EBER test was positive, indicating that LELC found in uncommon regions may also have close etiopathogenetic linkage with EBV infection.




Figure 1. Magnetic resonance imaging (MRI) findings. A, On MRI, the mass in the right liver appeared hypointense on T1-weighted images. B, The mass appeared inhomogeneous hyperintense on DWI-weighted images. D, On contrast-enhanced MRI, the mass was slightly enhanced.

The associations between serum tumor markers and LELC are still unclear. Elevated CA 125 can be found in adenocarcinoma and squamous cell carcinoma, whereas CYFRA 21-1 may be elevated in squamous cell carcinoma.^[15] We found elevated CA 125 and CYFRA 21-1 in our patient, which is consistent with a previous study that recommended the use of CA 125 and

CYFRA 21-1 to monitor LELC activity and its response to treatment.^[16] On the contrary, the patient's serum levels of AFP and CA 19-9 were unremarkable, which may be helpful for distinguishing LELC from primary liver tumors, such as HCC and intrahepatic cholangiocarcinoma.^[17,18] LELC appeared similar to in situ malignant tumors on CT or MRI, which show




Figure 2. Positron emission tomography/computed tomography findings. A, The imaging revealed a 2.3-cm hypodense lesion in the posterior mediastinum, which shows significantly different levels of FDG uptake (SUV maxy \approx 8.1). B, The imaging revealed a 6.7-cm hypodense lesion in the S6 lobe of the liver with remarkable FDG uptake (SUV max \approx 8.1).




Figure 3. Microscopic examination (the posterior mediastinum specimen). Microscopically, in the solid tumor, abundant poorly differentiated, atypical, large epithelial cells with an eosinophilic cytoplasm were found (A, B, HE × 40). Immunohistochemically, CK (pan), CK (5/6), P63, and EBER (C, D, E, F × 100) were positive.

fast inward and outward flow when contrasted. Park et al^[19] reported that F-18 FDG PET/CT shows high sensitivity for lymphoepithelioma-like gastric carcinoma as well as distant metastases, consistent with the findings in our patient whose 2 regions showed high sensitivity. PET/CT is thought to reliably detect occult carcinomas in different regions, and it allowed us to identify the primary tumor after the biopsy data raised our suspicions. Based on our case, we recommend the use of PET/CT when LELC is suspected in uncommon regions such as the liver.

The precise diagnosis was made by pathology, and the immunohistochemical findings showed abundant poorly differentiated atypical large epithelial cells with an eosinophilic cytoplasm and high expression of CK, CK5/6, and P63.^[20] We arrived at this patient's diagnosis by performing the liver biopsy first. Although it was difficult to determine the primary region of origin for this patient's tumor, we believe the diagnosis of posterior mediastinal LELC accompanied by liver metastasis is correct for the following reasons. First, LEL-HCC is quite rare, with only approximately 40 cases reported to date.^[21] In addition, HBV or HCV infection and liver cirrhosis are common in these tumors. The vast majority of hepatic cases are negative for EBV by ISH and sequencing,^[5] but LELC of the mediastinum is common. Moreover, the pathologist thought it was difficult to determine the region of LELC origin based on these uncommon regions. They found that there are no significant differences in cell morphology and immunohistochemistry between the 2 specimens and, combined with the similar imaging findings, believed that the mediastinum was more likely a primary site, and the locus in the liver was more likely to metastasize.

Standard treatments for LELC have not been established. Currently, first-line treatment of LEL-HCC includes liver resection and liver transplantation.^[21] Most patients with pulmonary lymphoepithelioma-like carcinoma (PLELC) undergo radical resection as the primary treatment when diagnosed at an early and resectable stage.^[22] A conservative management strategy for submucosal invasion treated by endoscopic submucosal dissection was considered for early stomach LELC.^[23] Although chemotherapy was thought to be a suitable treatment for patients with advanced stage PLELC, radiotherapy was more often used in breast LELC.^[24] Liang et al^[25] recommended platinum-based drugs combined with thirdgeneration chemotherapy as first-line treatment for PLELC. In addition, some researchers have seen positive results using PD1/PD-L1-targeting immunotherapy for different types of LELC.^[26,27]

Our patient was in an advanced stage, and the choice of treatment was challenging. The overall survival rate for patients with advanced LELC is low. Tay et al^[28] reported 5-year survival rates for advanced stage patients with PLELC in Singapore as less than 10%. Combination therapy is the best option to achieve the best possible outcome. Radical resection of hepatic metastases from colonic carcinoma has been shown to increase the 5-year survival rate from 0 to 5% to 25% to 40%.^[29] In a meta-analysis comparing the efficacy of surgical treatment with that of palliative care for 1147 patients with hepatic metastasis from pancreatic carcinoma, the 1-year survival rates were 52.8% and 27.1%, respectively, and the 3-year survival rates were 17.2% and 3.7%, respectively.^[30] For our patient, she was young, the focus was limited to 2 resectable sites, and the efficiency of nonsurgical treatment, such as chemotherapy or radiotherapy, was not satisfactory. To improve her treatment outcome, we opted to perform the surgery in coordination with doctors from the thoracic surgery department, as the tumor was well encapsulated and did not have microvascular invasion. Whether postoperative chemotherapy is effective in cases of LEL-HCC remains unknown due to a lack of data. Given the immunohistochemical finding that Ki-67 staining was present in more than 40% of cells, we chose paclitaxel and cisplatin as adjuvant chemotherapy for our patient to reduce the risk of recurrence. Unfortunately, we noted recurrence after 4 courses of adjuvant chemotherapy over a period of 4 months. More studies on advanced LELC with resectable metastasis are necessary to determine whether postoperative chemotherapy is beneficial.

Author contributions

Conceptualization: Xiao-Hui Qian, Dong-Kai Zhou. Supervision: Wei-Lin Wang and Dong-Kai Zhou. Writing – original draft: Xiao-Hui Qian. Writing – review & editing: Wei-Lin Wang.

References

- Gollom J. Lymphoepithelioma of the nasopharynx. Can Med Assoc J 1945;52:509–10.
- [2] Ma H, Lin Y, Wang L, et al. Primary lymphoepithelioma-like carcinoma of salivary gland: sixty-nine cases with long-term follow-up. Head Neck 2014;36:1305–12.
- [3] Li Z, Li Y, Li N, et al. Positron emission tomography/computed tomography outperforms MRI in the diagnosis of local recurrence and residue of nasopharyngeal carcinoma: an update evidence from 44 studies. Cancer Med 2019;8:67–79.
- [4] Chetty R. Gastrointestinal cancers accompanied by a dense lymphoid component: an overview with special reference to gastric and colonic medullary and lymphoepithelioma-like carcinomas. J Clin Pathol 2012;65:1062–5.
- [5] Labgaa I, Stueck A, Ward SC. Lymphoepithelioma-like carcinoma in liver. Am J Pathol 2017;187:1438–44.
- [6] Pan H, Song L, Sun LR. Nephrotic syndrome: first presentation of lymphoepithelioma-like thymic carcinoma. Br J Hosp Med (Lond) 2019;80:52–3.
- [7] Kennedy RA. WHO is in and WHO is out of the mouth, salivary glands, and jaws sections of the 4th edition of the WHO classification of head and neck tumours. Br J Oral Maxillofac Surg 2018;56:90–5.
- [8] Yeh YC, Kao HL, Lee KL, et al. Epstein-Barr virus-associated pulmonary carcinoma: proposing an alternative term and expanding the histologic spectrum of lymphoepithelioma-like carcinoma of the lung. Am J Surg Pathol 2019;43:211–9.
- [9] Xie M, Wu X, Wang F, et al. Clinical significance of plasma Epstein-Barr virus DNA in pulmonary lymphoepithelioma-like carcinoma (LELC) patients. J Thorac Oncol 2018;13:218–27.
- [10] Nemolato S, Fanni D, Naccarato AG, et al. Lymphoepitelioma-like hepatocellular carcinoma: a case report and a review of the literature. World J Gastroenterol 2008;14:4694–6.
- [11] Canete-Portillo S, Clavero O, Sanchez DF, et al. Medullary carcinoma of the penis: a distinctive HPV-related neoplasm: a report of 12 cases. Am J Surg Pathol 2017;41:535–40.
- [12] Shinozaki-Ushiku A, Kunita A, Fukayama M. Update on Epstein-Barr virus and gastric cancer (review). Int J Oncol 2015;46:1421–34.
- [13] Castro CY, Ostrowski ML, Barrios R, et al. Relationship between Epstein-Barr virus and lymphoepithelioma-like carcinoma of the lung: a clinicopathologic study of 6 cases and review of the literature. Hum Pathol 2001;32:863–72.
- [14] Rathore R, Arora VK, Singh B. Lymphoepithelioma-like carcinoma of cervix: cytological features on conventional cervical smear. Diagn Cytopathol 2017;45:239–42.
- [15] Molina R, Auge JM, Bosch X, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol 2009;30:121–9.
- [16] Qin Y, Gao G, Xie X, et al. Clinical features and prognosis of pulmonary lymphoepithelioma-like carcinoma: summary of eighty-five cases. Clin Lung Cancer 2019;20:e329–37.
- [17] Renne SL, Woo HY, Allegra S, et al. Vessels encapsulating tumor clusters (VETC) is a powerful predictor of aggressive hepatocellular carcinoma. Hepatology 2019;71:183–95.
- [18] Edoo MIA, Chutturghoon VK, Wusu-Ansah GK, et al. Serum biomarkers AFP, CEA and CA19-9 combined detection for early diagnosis of hepatocellular carcinoma. Iran J Public Health 2019;48: 314–22.
- [19] Park S, Lee D, Lee KM, et al. Clinical usefulness of F-18 FDG PET in lymphoepithelioma-like gastric carcinoma. Eur J Radiol 2017;94:160–6.
- [20] Jiang WY, Wang R, Pan X-F, et al. Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma. J Thorac Dis 2016;8:2610–6.
- [21] Cacciato Insilla A, Faviana P, Pollina LE, et al. Lymphoepithelioma-like hepatocellular carcinoma: case report and review of the literature. World J Gastroenterol 2015;21:10468–74.
- [22] Liang Y, Shen C, Che G, et al. Primary pulmonary lymphoepitheliomalike carcinoma initially diagnosed as squamous metaplasia: a case report and literature review. Oncol Lett 2015;9:1767–71.
- [23] Lee JY, Kim KM, Min BH, et al. Epstein-Barr virus-associated lymphoepithelioma-like early gastric carcinomas and endoscopic submucosal dissection: case series. World J Gastroenterol 2014;20: 1365–70.
- [24] Fadila K, Faycal A, Lamiaa J, et al. Lymphoepithelioma-like carcinoma of the breast: a case report and review of the literature. Pan Afr Med J 2019;32:18.

- [25] Liang Y, Wang L, Zhu Y, et al. Primary pulmonary lymphoepitheliomalike carcinoma: fifty-two patients with long-term follow-up. Cancer 2012;118:4748–58.
- [26] Narayanan A, Knollmann FD, Walby JAS, et al. EBV-positive primary pulmonary lymphoepithelioma-like carcinoma response to PD-L1 blockade. Clin Lung Cancer 2019;20:e238–41.
- [27] Suster D, Pihan G, Mackinnon AC, et al. Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus. Mod Pathol 2018;31: 1801–6.
- [28] Tay CK, Chua YC, Takano A, et al. Primary pulmonary lymphoepithelioma-like carcinoma in Singapore. Ann Thorac Med 2018;13: 30–5.
- [29] Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006;42:2212–21.
- [30] Yu X, Gu J, Fu D, et al. Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma? A systematic review and meta-analysis. Int J Surg 2017;48:149–54.